Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis / 대한내과학회지
Korean Journal of Medicine
; : 294-298, 2019.
Article
en En
| WPRIM
| ID: wpr-759932
Biblioteca responsable:
WPRO
ABSTRACT
Bedaquiline and delamanid were recently approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Korea. A treatment duration of 24 weeks was established based on phase 2 clinical trial data, although the combined use of these two drugs is typically not recommended because it may exaggerate QT prolongation. Here, we present a case of prolonged treatment (48 weeks) with a combination of bedaquiline and delamanid for pulmonary MDR-TB. The patient had previously been diagnosed with extensively drug-resistant TB but had been left untreated for the past 9 years due to a shortage of effective drugs. A combination of bedaquiline and delamanid successfully treated MDR-TB, highlighting the potential efficacy of these drugs for patients with drug-resistant TB infections.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Tuberculosis
/
Tuberculosis Resistente a Múltiples Medicamentos
/
Corea (Geográfico)
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Korean Journal of Medicine
Año:
2019
Tipo del documento:
Article